scholarly journals Current Treatment and Recent Clinical Research in Alzheimer's Disease

2010 ◽  
Vol 77 (1) ◽  
pp. 3-16 ◽  
Author(s):  
Judith Neugroschl ◽  
Mary Sano
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Research ◽  
Current Treatment

Main Plant Extracts’ Active Properties Effective on Scopolamine-Induced Memory Loss

2017 ◽  
Vol 32 (7) ◽  
pp. 418-428 ◽  
Author(s):  
Ioana-Miruna Balmus ◽  
Alin Ciobica
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Plant Extracts ◽  
Current Knowledge ◽  
Symptomatic Relief ◽  
Memory Loss ◽  
Current Treatment ◽  
General Effect ◽  
Function Loss ◽  
Theory Research

Alzheimer’s disease leads to progressive cognitive function loss, which may impair both intellectual capacities and psychosocial aspects. Although the current knowledge points to a multifactorial character of Alzheimer’s disease, the most issued pathological hypothesis remains the cholinergic theory. The main animal model used in cholinergic theory research is the scopolamine-induced memory loss model. Although, in some cases, a temporary symptomatic relief can be obtained through targeting the cholinergic or glutamatergic neurotransmitter systems, no current treatment is able to stop or slow cognitive impairment. Many potentially successful therapies are often blocked by the blood–brain barrier since it exhibits permeability only for several classes of active molecules. However, the plant extracts’ active molecules are extremely diverse and heterogeneous regarding the biochemical structure. In this way, many active compounds constituting the recently tested plant extracts may exhibit the same general effect on acetylcholine pathway, but on different molecular ground, which can be successfully used in Alzheimer’s disease adjuvant therapy.

Constructing a Local Potential Participant Registry to Improve Alzheimer’s Disease Clinical Research Recruitment

2018 ◽  
Vol 63 (3) ◽  
pp. 1055-1063 ◽  
Author(s):  
Joshua D. Grill ◽  
Dan Hoang ◽  
Daniel L. Gillen ◽  
Chelsea G. Cox ◽  
Adrijana Gombosev ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Research ◽  
Local Potential ◽  
Potential Participant ◽  
Research Recruitment

scholarly journals Reduced memory and executive functioning significantly relates to participation in early phase clinical research in Alzheimer's disease

2020 ◽  
Vol 16 (S9) ◽  
Author(s):  
Lovingly Park ◽  
Lev Gertsik ◽  
Zyanya Mendoza ◽  
Lydia Morris ◽  
Claudia Aguilar ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Executive Functioning ◽  
Clinical Research ◽  
Early Phase

Magnetic Resonance Imaging Based Clinical Research in Alzheimer's Disease

2012 ◽  
Vol 31 (s3) ◽  
pp. S5-S18 ◽  
Author(s):  
Nicolás Fayed ◽  
Pedro J. Modrego ◽  
Gulillermo Rojas Salinas ◽  
José Gazulla
Keyword(s):  
Magnetic Resonance Imaging ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Magnetic Resonance ◽  
Clinical Research ◽  
Resonance Imaging

scholarly journals Biomarkers in Mild Stages of Alzheimer’s disease: Utility in clinical practice and their relation with nutritional and lifestyle factors

2016 ◽  
Vol 6 (10) ◽  
pp. 627
Author(s):  
Carol Dillon ◽  
Patricio Pérez Leguizamon ◽  
Silvina Heisecke ◽  
Diego M. Castro ◽  
Jorge Lopez Camelo ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Clinical Practice ◽  
Clinical Research ◽  
Lifestyle Factors ◽  
Clinical Settings ◽  
Treatment Methods ◽  
Primary Endpoints ◽  
Alzheimer’S Disease Dementia

Background: The use of biomarkers in basic and clinical research as well as in clinical practice has become so common that their presence as primary endpoints in clinical trials is now accepted. A biomarker refers to a broad subcategory of medical signs. The aims of this article are to consider the of use biomarkers in Mild stages of Alzheimer’s disease (AD) in research and clinical settings, in addition to defining their utility in clinical practice relating this with nutritional and lifestyle factors as possible treatment. Methods: We searched MEDLINE, PubMed, and AgeLine databases using different keywords.Conclusions: A summary of the utility of biomarkers in AD and nutritional and lifestyle factors used as treatment in mild stages are described.Key words: Biomarkers, Alzheimer’s disease, Dementia, Utility, Clinical practice, Nutritional

Sign in / Sign up

Export Citation Format

Share Document